Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.8.0.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Net revenues - External $ 1,601,661 $ 684,265  
(Loss) income from operations (3,712,024) (3,556,257)  
Depreciation and amortization 333,515 426,929  
Capital expenditures 990,540  
Total assets 6,137,770   $ 6,290,794
Clinical Laboratory Operations [Member]      
Net revenues - External 45,586 684,265  
(Loss) income from operations (756,083) (1,292,275)  
Depreciation and amortization 295,474 434,468  
Capital expenditures (100,382)  
Total assets 1,019,946   1,503,520
Hospital Operations [Member]      
Net revenues - External 1,556,075  
(Loss) income from operations (1,472,600) (467,316)  
Depreciation and amortization 37,728  
Capital expenditures 1,090,922  
Total assets 2,788,059   2,549,504
Corporate [Member]      
(Loss) income from operations (1,483,341) (1,804,517)  
Depreciation and amortization 314 312  
Total assets 3,510,297   3,436,773
Eliminations [Member]      
(Loss) income from operations 7,851  
Depreciation and amortization $ (7,851)  
Total assets (1,424,496)   (1,454,570)
Assets of AMSG and HTS Classified As Held For Sale[Member]      
Total assets $ 243,963   $ 255,566